This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2022.
Program Description
The management of patients with multiple myeloma (MM) can be challenging due to rapid therapy advances and complexity of new regimens. Proteasome inhibitors (PIs) have become an important cornerstone of treatment. This program will present data from recent clinical trials on the use of PIs in combination therapies. It is especially important for pharmacists to be aware of methods to promote patient adherence to therapy, as regimens are complex and associated with adverse effects. The program will review best practices for the prevention and treatment of myeloma-related bone disease and maintenance of bone health in patients with MM. Faculty will also discuss evolving digital technology and mobile health tools that pharmacists can utilize in the management of patients with MM to improve patient care and communication. This activity will feature a patient perspective interview in which pharmacists will gain insight into a patient’s experience with MM throughout the course of disease from diagnosis to treatment, as well as challenges and management of adverse effects of therapy.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 29, 2022
Expiration date: April 29, 2023
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Apply knowledge of safety and efficacy data of proteasome inhibitors in multiple myeloma (MM) to therapy selection
- Customize a patient-specific supportive care plan to prevent or minimize skeletal-related events as a result of MM
- Explore strategies to improve medication adherence via digital technology
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
